6-Sulfo LacNAc, a novel carbohydrate modification of PSGL-1, defines an inflammatory type of human dendritic cells
Knut Schäkel, Reiji Kannagi, Bernhard Kniep, Yoshiko Goto, Chikako Mitsuoka, Jörg Zwirner, Afsaneh Soruri, Matthias von Kietzell, E Rieber, Knut Schäkel, Reiji Kannagi, Bernhard Kniep, Yoshiko Goto, Chikako Mitsuoka, Jörg Zwirner, Afsaneh Soruri, Matthias von Kietzell, E Rieber
Abstract
The monoclonal antibody M-DC8 defines a major subset of human blood dendritic cells (DCs). Here we identify the M-DC8 structure as 6-sulfo LacNAc, a novel carbohydrate modification of the P selectin glycoprotein ligand 1 (PSGL-1). In contrast to previously described blood DCs, M-DC8+ DCs lack the cutaneous lymphocyte antigen (CLA) on PSGL-1 and fail to bind P and E selectin. Yet they express anaphylatoxin receptors (C5aR and C3aR) and the Fcgamma receptor III (CD16), which recruit cells to inflammatory sites. While sharing with DC1 the expression of myeloid markers and a potent capacity to prime T cells in vitro, M-DC8+ DCs produce far more TNF-alpha in response to the bacterial endotoxin lipopolysaccharide (LPS). Thus, 6-sulfo LacNAc-expressing DCs appear as a novel proinflammatory DC subset.
Source: PubMed